Loading organizations...
§ Private Profile · New York City, NY, USA
A SPAC formed to acquire private healthcare, life sciences, and medical technology businesses. Liquidated July 2023.
Key people at ARYA Sciences Acquisition Corp V.
ARYA Sciences Acquisition Corp V was a New York-based special purpose acquisition company formed to effect a merger, share exchange, or asset acquisition with a private business. The blank-check firm primarily targeted established North American and European companies operating within the broader healthcare, biotechnology, and medical technology sectors. During its initial public offering in July 2021, the entity successfully raised $149.5 million in total proceeds to pursue target businesses with estimated enterprise valuations ranging from $300 million to over $500 million. The public offering was underwritten by Jefferies and backed by the life sciences investment firm Perceptive Advisors, though the shell company ultimately liquidated its trust account in July 2023 without completing a finalized business combination. ARYA Sciences Acquisition Corp V was founded in 2021 by Perceptive Advisors executives Joseph Edelman and Adam Stone.
Key people at ARYA Sciences Acquisition Corp V.
ARYA Sciences Acquisition Corp V (ARYE) is a blank check company, also known as a special purpose acquisition company (SPAC), with no significant independent operations.[1][2][3][4][5] Incorporated in 2020 as a Cayman Islands exempted company and based in New York, it was formed to effect a merger, share exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses, specifically targeting North American or European companies in the life sciences and medical technology sectors.[1][2][7] As a SPAC, its mission centers on providing a public market pathway for such targets, raising capital through an IPO to fund the deal, with a focus on high-growth healthcare innovations; it holds minimal revenue ($0 annual sales) and reports net income primarily from interest on trust assets.[2]
The company maintains a small market capitalization of around $199 million, with 19.2 million shares outstanding, 76% institutional ownership, and 22% insider holdings as of recent data.[2] Note that ARYA Sciences Acquisition Corp IV (a related entity) completed a reverse merger with Adagio Medical, Inc. as of July 31, 2024, highlighting the SPAC model's role in biotech de-SPAC transactions, though ARYE itself shows no completed merger in available records.[1]
ARYA Sciences Acquisition Corp V was incorporated in 2020 as a newly organized blank check company under Cayman Islands law, headquartered at 51 Astor Place, 10th Floor, New York, NY.[2][7] It emerged as part of the broader ARYA Sciences SPAC franchise, sponsored by affiliates with expertise in life sciences investments, amid a surge in SPAC IPOs during 2020-2021 to capitalize on public market enthusiasm for healthcare tech.[7] Key partners or sponsors are not detailed in profiles, but the firm's focus evolved from general SPAC structure to a targeted thesis on life sciences and medtech in North America and Europe, reflecting sponsor networks in biotech dealmaking.[1][2]
Early traction aligned with the SPAC boom, going public on NASDAQ under ticker ARYE (Class A shares), raising funds held in trust for a future business combination.[2][6] As of mid-2023, shares traded around $10.36, typical for pre-merger SPACs maintaining net asset value.[6] No pivotal merger has been announced for ARYE V specifically, positioning it as a dormant vehicle awaiting a target.
ARYE V rides the SPAC wave in biotech, a trend peaking in 2020-2022 that democratized public access for life sciences firms amid rising demand for medtech post-COVID.[1][3] Timing mattered as low-interest environments fueled SPAC IPOs, enabling quick liquidity for startups in genomics, diagnostics, and devices—sectors facing high R&D costs and long clinical timelines.[2][7] Market forces like aging populations, AI-drug discovery, and regulatory tailwinds (e.g., FDA fast-tracks) favor its targets, while influencing the ecosystem by accelerating IPOs for pre-revenue innovators.[1]
In a cooling SPAC market by 2025, ARYE exemplifies resilience for niche healthcare plays, potentially bridging private VC funding gaps amid higher rates; its unmerged status underscores selective deployment amid redemption pressures.[2][6]
ARYE V remains in pre-merger limbo, likely pursuing a life sciences or medtech target to unlock value through a de-SPAC, with shares anchored near $10 amid low volatility.[2][6] Trends like precision medicine, AI therapeutics, and European biotech consolidation will shape its path, potentially driving a deal in 2026 if market sentiment rebounds. Influence may evolve via a successful merger, humanizing its SPAC origins into a public biotech force—watch for SEC filings signaling the next combination to ignite growth from its current $199M shell.[2][1]
